Frontiers in Anti-Infective Drug Discovery: Volume 8
By Atta-ur-Rahman and M. Iqbal Choudhary
()
About this ebook
Atta-ur-Rahman
Atta-ur-Rahman, Professor Emeritus, International Center for Chemical and Biological Sciences (H. E. J. Research Institute of Chemistry and Dr. Panjwani Center for Molecular Medicine and Drug Research), University of Karachi, Pakistan, was the Pakistan Federal Minister for Science and Technology (2000-2002), Federal Minister of Education (2002), and Chairman of the Higher Education Commission with the status of a Federal Minister from 2002-2008. He is a Fellow of the Royal Society of London (FRS) and an UNESCO Science Laureate. He is a leading scientist with more than 1283 publications in several fields of organic chemistry.
Read more from Atta Ur Rahman
Solving Problems with NMR Spectroscopy Rating: 3 out of 5 stars3/5Applications of NMR Spectroscopy: Volume 6 Rating: 0 out of 5 stars0 ratingsOne and Two Dimensional NMR Spectroscopy Rating: 0 out of 5 stars0 ratingsUrban Disasters and Resilience in Asia Rating: 0 out of 5 stars0 ratingsFrontiers in Anti-Infective Drug Discovery: Volume 6 Rating: 0 out of 5 stars0 ratingsFrontiers in Clinical Drug Research - Alzheimer Disorders: Volume 6 Rating: 0 out of 5 stars0 ratingsFrontiers in Clinical Drug Research - Anti Infectives: Volume 3 Rating: 0 out of 5 stars0 ratingsAnti-Angiogenesis Drug Discovery and Development: Volume 4 Rating: 0 out of 5 stars0 ratingsAdvances in Organic Synthesis: Volume 7 Rating: 0 out of 5 stars0 ratingsApplications in Food Sciences Rating: 0 out of 5 stars0 ratingsGenes in Health and Disease Rating: 0 out of 5 stars0 ratingsFrontiers in Drug Design & Discovery: Volume 8 Rating: 0 out of 5 stars0 ratingsFrontiers in Natural Product Chemistry: Volume 8 Rating: 0 out of 5 stars0 ratingsFrontiers in Clinical Drug Research - Anti Infectives: Volume 8 Rating: 0 out of 5 stars0 ratingsAdvances in Cancer Drug Targets: Volume 3 Rating: 0 out of 5 stars0 ratingsAnti-Angiogenesis Drug Discovery and Development: Volume 5 Rating: 0 out of 5 stars0 ratingsAnti-obesity Drug Discovery and Development: Volume 4 Rating: 0 out of 5 stars0 ratingsFrontiers in Stem Cell and Regenerative Medicine Research: Volume 10 Rating: 0 out of 5 stars0 ratingsFrontiers in Clinical Drug Research - Hematology: Volume 2 Rating: 0 out of 5 stars0 ratingsCardiovascular Diseases Rating: 0 out of 5 stars0 ratingsFrontiers in Anti-Cancer Drug Discovery: Volume 10 Rating: 0 out of 5 stars0 ratingsFrontiers in Anti-Cancer Drug Discovery: Volume 12 Rating: 0 out of 5 stars0 ratingsFrontiers in Clinical Drug Research - CNS and Neurological Disorders: Volume 10 Rating: 0 out of 5 stars0 ratingsScience of Spices and Culinary Herbs: Volume 3 Rating: 0 out of 5 stars0 ratingsFrontiers in Clinical Drug Research - Anti-Allergy Agents: Volume 4 Rating: 0 out of 5 stars0 ratingsFrontiers in Clinical Drug Research - Anti-Cancer Agents: Volume 5 Rating: 0 out of 5 stars0 ratingsFrontiers in Clinical Drug Research - Diabetes and Obesity: Volume 2 Rating: 0 out of 5 stars0 ratingsFrontiers in Clinical Drug Research - Alzheimer Disorders: Volume 7 Rating: 0 out of 5 stars0 ratingsFrontiers in Cardiovascular Drug Discovery: Volume 4 Rating: 0 out of 5 stars0 ratingsAdvances in Organic Synthesis: Volume 13 Rating: 0 out of 5 stars0 ratings
Related to Frontiers in Anti-Infective Drug Discovery
Related ebooks
Frontiers in Anti-Infective Drug Discovery: Volume 8 Rating: 0 out of 5 stars0 ratingsCutting Edge Techniques in Biophysics, Biochemistry and Cell Biology: From Principle to Applications Rating: 0 out of 5 stars0 ratingsNanopharmacology and Nanotoxicology: Clinical Implications and Methods Rating: 0 out of 5 stars0 ratingsAnti-infective Research and Development: Updates on Infection Mechanisms and Treatments Rating: 0 out of 5 stars0 ratingsFrontiers in Anti-Infective Drug Discovery: Volume 7 Rating: 0 out of 5 stars0 ratingsFrontiers in Computational Chemistry: Volume 5 Rating: 0 out of 5 stars0 ratingsAnti-Angiogenesis Drug Discovery and Development: Volume 4 Rating: 0 out of 5 stars0 ratingsMushrooms: A Wealth of Nutraceuticals and An Agent of Bioremediation Rating: 0 out of 5 stars0 ratingsApplications of NMR Spectroscopy Volume 7 Rating: 0 out of 5 stars0 ratingsFrontiers in Drug Design & Discovery: Volume 11 Rating: 0 out of 5 stars0 ratingsAdvances in Cancer Nanotheranostics for Experimental and Personalized Medicine Rating: 0 out of 5 stars0 ratingsInfectious Diseases Rating: 0 out of 5 stars0 ratingsCoronaviruses: Volume 2 Rating: 0 out of 5 stars0 ratingsAn Introduction to Mycosporine-Like Amino Acids Rating: 0 out of 5 stars0 ratingsFrontiers in CNS Drug Discovery: Volume 3 Rating: 0 out of 5 stars0 ratingsApplications in Food Sciences Rating: 0 out of 5 stars0 ratingsLaser Optofluidics in Fighting Multiple Drug Resistance Rating: 0 out of 5 stars0 ratingsFrontiers in Anti-Infective Agents: Volume 6 Rating: 0 out of 5 stars0 ratingsA Comprehensive Guide to Nanoparticles in Medicine Rating: 0 out of 5 stars0 ratingsProbing Intracellular Regulation Rating: 0 out of 5 stars0 ratingsRecent Advances in Biosensor Technology: Volume 1 Rating: 0 out of 5 stars0 ratingsBio-Inspired Nanotechnology Rating: 0 out of 5 stars0 ratingsCurrent Developments in the Detection and Control of Multi Drug Resistance Rating: 0 out of 5 stars0 ratingsFrontiers in Anti-Cancer Drug Discovery: Volume 10 Rating: 0 out of 5 stars0 ratingsAdvances in Cancer Drug Targets: Volume 1 Rating: 0 out of 5 stars0 ratingsRecent Trends and The Future of Antimicrobial Agents - Part I Rating: 0 out of 5 stars0 ratingsFrontiers in Anti-Cancer Drug Discovery: Volume 12 Rating: 0 out of 5 stars0 ratingsFrontiers in Computational Chemistry: Volume 6 Rating: 0 out of 5 stars0 ratingsBiotechnology and Drug Development for Targeting Human Diseases Rating: 0 out of 5 stars0 ratingsNanomedicinal Approaches Towards Cardiovascular Disease Rating: 0 out of 5 stars0 ratings
Medical For You
Passionista: The Empowered Woman's Guide to Pleasuring a Man Rating: 4 out of 5 stars4/5The Vagina Bible: The Vulva and the Vagina: Separating the Myth from the Medicine Rating: 5 out of 5 stars5/5The Diabetes Code: Prevent and Reverse Type 2 Diabetes Naturally Rating: 4 out of 5 stars4/5Mating in Captivity: Unlocking Erotic Intelligence Rating: 4 out of 5 stars4/5Mediterranean Diet Meal Prep Cookbook: Easy And Healthy Recipes You Can Meal Prep For The Week Rating: 5 out of 5 stars5/5ATOMIC HABITS:: How to Disagree With Your Brain so You Can Break Bad Habits and End Negative Thinking Rating: 5 out of 5 stars5/5Tight Hip Twisted Core: The Key To Unresolved Pain Rating: 4 out of 5 stars4/5Adult ADHD: How to Succeed as a Hunter in a Farmer's World Rating: 4 out of 5 stars4/5WomanCode: Perfect Your Cycle, Amplify Your Fertility, Supercharge Your Sex Drive, and Become a Power Source Rating: 4 out of 5 stars4/5What Happened to You?: Conversations on Trauma, Resilience, and Healing Rating: 4 out of 5 stars4/5The 40 Day Dopamine Fast Rating: 4 out of 5 stars4/5Period Power: Harness Your Hormones and Get Your Cycle Working For You Rating: 4 out of 5 stars4/5Peptide Protocols: Volume One Rating: 4 out of 5 stars4/5Holistic Herbal: A Safe and Practical Guide to Making and Using Herbal Remedies Rating: 4 out of 5 stars4/5The Amazing Liver and Gallbladder Flush Rating: 5 out of 5 stars5/5Gut: The Inside Story of Our Body's Most Underrated Organ (Revised Edition) Rating: 4 out of 5 stars4/5ketoCONTINUUM Consistently Keto For Life Rating: 5 out of 5 stars5/5Living Daily With Adult ADD or ADHD: 365 Tips o the Day Rating: 5 out of 5 stars5/5The White Coat Investor: A Doctor's Guide to Personal Finance and Investing Rating: 4 out of 5 stars4/5Woman: An Intimate Geography Rating: 4 out of 5 stars4/5Women With Attention Deficit Disorder: Embrace Your Differences and Transform Your Life Rating: 5 out of 5 stars5/5Working Stiff: Two Years, 262 Bodies, and the Making of a Medical Examiner Rating: 4 out of 5 stars4/5Blind Eye: The Terrifying Story Of A Doctor Who Got Away With Rating: 4 out of 5 stars4/5The Art of Dying Well: A Practical Guide to a Good End of Life Rating: 4 out of 5 stars4/5
Reviews for Frontiers in Anti-Infective Drug Discovery
0 ratings0 reviews
Book preview
Frontiers in Anti-Infective Drug Discovery - Atta-ur-Rahman
Eradication of Helicobacter pylori Infection with Non-Bismuth Quadruple Concomitant Therapy
Javier P. Gisbert*, Adrian G. McNicholl
Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autonoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
Abstract
Background: The main recommended regimens to eradicate Helicobacter pylori infection fail in ≥20% of the cases. Several substitutes for triple therapies have been proposed, and non-bismuth quadruple therapy is one of the most widely used.
Aim: To systematically review the efficacy of non-bismuth quadruple regimen (proton pump inhibitor, clarithromycin, amoxicillin and a nitroimidazole) in the eradication of H. pylori infection.
Methods: Bibliographical searches were performed in MEDLINE/EMBASE and relevant congresses. We pooled studies evaluating the concomitant regimen, and of the randomized controlled trials comparing concomitant vs. standard triple therapy, and concomitant vs. sequential therapy.
Results: Fifty-five studies were included (6,906 patients). The meta-analysis showed that concomitant regimen offers an overall eradication rate of 87%. A sub-analysis of studies comparing one-to-one concomitant and triple therapies showed an odds ratio of 2.14 (95% CI=1.51-3.04) towards higher efficacy with concomitant regimen. This figure increased up to 2.41 (95% CI=1.80-3.24; 85% vs. 72%) when comparing arms lasting the same number of days. We also sub-analyzed the comparative efficacy between non-bismuth quadruple concomitant and sequential treatments, and concomitant achieved an odds ratio of 1.49 (95% CI=1.21-1.85) towards higher eradication results than sequential regimen.
Conclusions: Non-bismuth quadruple (concomitant) therapy achieves high efficacy in H. pylori eradication, superior to standard triple and sequential therapy. Concomitant may be more appropriate than sequential therapy for patients with clarithromycin and/or metronidazole resistance. Higher acid suppression and/or longer duration are optimizations that can increase even more its efficacy.
Keywords: Amoxicillin, Clarithromycin, Concomitant therapy, Helicobacter pylori, Metronidazole, Non-bismuth quadruple, Proton pump inhibitor, Resistance, Sequential therapy, Treatment.
* Corresponding author Javier P. Gisbert: Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autonoma de Madrid (UAM), Madrid, Spain; Tel.: 34-913093911; Fax: 34-915204013, E-mail: javier.p.gisbert@gmail.com
INTRODUCTION
Approximately fifty percent of the world population is infected by Helicobacter pylori, a bacterium linked to a broad range of upper gastrointestinal conditions such as gastritis, peptic ulcer disease, and gastric cancer [1]. The most commonly used therapy for the eradication of H. pylori, traditionally recommended by international consensus, is the proton pump inhibitor (PPI)–based, standard triple therapy, adding two antibiotics (clarithromycin plus amoxicillin or metronidazole) to a PPI [2-6]. However, the eradication rates with this regimen have fallen considerably [7, 8]. Previous meta-analyses (with more than 53,000 included patients) showed an efficacy below 80% [9, 10]. Therefore, recent debate has been raised regarding how ethical it is to continue using standard triple therapy, and alternative approaches have been recommended [11]. Although, efforts to improve eradication prolonging triple therapy’s duration have been tested, data have not consistently provided significant benefits [12, 13]. Consequently, new combinations to improve treatment of naïve patients remain as an urgent need.
Sequential treatment involving a dual regimen with a PPI plus amoxicillin for the first 5 days followed by a triple regimen including a PPI, clarithromycin, and a nitroimidazole for the following 5 days, was proposed as an alternative [14]. Several randomized clinical trials and meta-analyses have shown that the sequential regimen was more effective than the standard triple [15-19]. Therefore, some consensus conferences suggested sequential regimen as a substitute to standard triple for the first-line eradication of H. pylori [20]. Nevertheless, results obtained by a meta-analysis by the Cochrane Collaboration [21] concluded that sequential regimen outcomes were heterogeneous, and that many of the latest manuscripts were unable to show any benefit from sequential over standard triple therapy. The conclusions of the meta-analysis were clear even though the pooled eradication rate was 85%, and a potential trend towards reduced efficacy was observed in the last years [21].
Sequential treatment faced another relevant issue, whether sequential administration was really necessary or if the 4 drugs could be given concurrently [14, 22, 23]. Questions were raised regarding the risk of failure to comply with the treatment due to regimen complexity [11, 24] Moreover, the combination of amoxicillin, clarithromycin and a nitroimidazole with a PPI has previously been evaluated as a concomitant regimen in 1998: two research teams, one in Japan and the other in Germany, recommended that this drug combination should be prescribed as a concomitant 4-drug, 3-antibiotic, known as non–bismuth quadruple therapy [25, 26], providing high efficacy even in short durations (>90% by intention-to-treat in 5-day regimens).
This non-bismuth quadruple concomitant
regimen has regained presence in recent years [27]. It is easy to convert the standard triple therapy (PPI-clarithromycin-amoxicillin) to concomitant therapy by adding of 500 mg of metronidazole (or tinidazole) twice daily [28]. Beware that concomitant
(taking all drugs all together) may cause confusion; this term is actually a misnomer, as all H. pylori treatments, except sequential therapy, could be called concomitant therapies. Nonetheless, this will be the name used hereafter as it has been the most common denomination in the literature.
OBJECTIVE
The aim of the present chapter is to perform a critical review of published evidence on the efficacy and safety of concomitant therapy in the eradication of H. pylori infection. We will review the following aspects: 1) Efficacy of the concomitant regimen; 2) Comparison between the concomitant regimen and standard triple therapy; 3) Comparison between the concomitant and the sequential therapies; 4) Effects of different variables on the efficacy of concomitant therapy; 5) How could we increase the efficacy of the concomitant treatment? and finally; 6) What are the results with the concomitant treatment in clinical practice? (the experience of the European registry on H. pylori management).
BIBLIOGRAPHICAL SEARCHES
Bibliographical searches were performed in MEDLINE and ENDBASE using the following keywords (all fields): ((concomitant OR quadruple OR concurrent OR ((amoxicillin OR amoxycillin) AND (metronidazole OR tinidazole OR nitroimidazole) AND clarithromycin) AND ("Helicobacter pylori OR
H. pylori"). No language restriction was applied. Bibliography from selected manuscripts and reviews were hand-searched to identify further relevant studies. Authors conducted a hand-search of communications from the American Digestive Disease Week, the International Workshop of the European Helicobacter Study Group, and the United European Gastroenterology Week. Summaries of the manuscripts selected in the different searches were reviewed, and screened for exclusion and inclusion criteria. In cases of duplicate reporting of studies or evidently based on overlapping study population, the latest valid report was considered.
EFFICACY OF THE CONCOMITANT REGIMEN
A summary of studies evaluating concomitant regimen’s efficacy is shown in Table 1 [25, 26, 29-80]. Concomitant combinations were prescribed homogenously, with only minimal alterations: the nitroimidazole (tinidazole or metronidazole) and the PPI (omeprazole, lansoprazole, rabeprazole, or esomeprazole) and. However, there was a wide duration range between three and fourteen days. The analysis of the 55 studies (6,906 patients) showed a pooled eradication percentage by intention-to-treat of 87%, with a 95% confidence interval (95% CI) ranging from 86 to 89% (Fig. 1). The data were pooled using the generic inverse variance method, which involves a weighted average of the effect estimates from the included studies. The weight for each study equals one divided by the square of the standard error (inverse of the variance) of the effect estimate. As population and regimens lengths were heterogeneous, a random effects model (DerSimonian and Laird) was applied to perform the meta-analysis (using Review Manager 5.0.25, developed by the Cochrane Collaboration).
Table 1 Studies evaluating the efficacy of non-bismuth quadruple (concomitant) regimen for the treatment of Helicobacter pylori infection.
ITT, intention-to-treat; PP, per-protocol.
RCT, randomized controlled trial. NC, non-controlled.
PUD, peptic ulcer disease; NUD, non-ulcer disease.
PPI, proton pump inhibitor (at standard dose); O, omeprazole; L, lansoprazole; R, rabeprazole; E, esomeprazole; A: amoxicillin; C, clarithromycin; M, metronidazole; T, tinidazole; R, roxithromycin.
od, once daily; bid: two times a day; tid: three times a day
¶Days of antibiotic treatment; †Pediatric patients; C¥Sustained release clarithromycin.
Fig. (1))
Meta-analysis of efficacy (intention-to-treat) of studies evaluating the concomitant regimen for the treatment of H. pylori infection.
COMPARISON BETWEEN CONCOMITANT AND STANDARD TRIPLE REGIMEN
The superiority of concomitant therapy over standard triple therapy has been confirmed in several randomized trials. A recent meta-analysis [81] evaluated 9 prospective studies treating H. pylori with a concomitant regimen for up to 7 days. Prescribed regimens generally lasted 5 days (ranging from 4 in one study to 7 in another). Overall, concomitant therapy achieved 90% intention-to-treat eradication (93% per-protocol). Moreover, the estimates of the meta-analysis of the 5 randomized controlled trials demonstrated the superiority of concomitant regimen over standard triple therapy (odds ratio of 2.86; 95% CI, 1.73-4.73).
For this chapter, we have updated these meta-analytical evaluations with more recent studies and have updated it including the new trials that have compared these two treatments. Table 2 describes the studies comparing the H. pylori eradication rate of concomitant regimen with that of standard triple therapy by intention-to-treat [25, 31, 39, 41, 42, 47, 48, 58, 60-62, 67, 68, 71, 73].
Table 2 Studies comparing the efficacy (intention-to-treat) of the concomitant regimen with that of standard triple therapy for the eradication of H. pylori infection.
PPI, proton pump inhibitor (at standard dose); O, omeprazole; L, lansoprazole; R, rabeprazole; E, esomeprazole; A: amoxicillin; C, clarithromycin; M, metronidazole; T, tinidazole.
od, once daily; bid: two times a day; tid: three times a day
¶Days of antibiotic treatment.
As summarized in Fig. (2), 2, 059 patients received the concomitant regimen and 2,268 the standard triple regimen. The former was more effective than the latter: 81% vs. 74% in the intention-to-treat analysis. The odds ratio for this comparison was 2.14 (95% CI, 1.51-3.04) (Fig. 2A). A sub-analysis was performed excluding those studies in which both treatments had different treatment durations between arms. This sub-analysis showed (Fig. 2B) that, when comparing both concomitant and triple therapies lasting the same number of days, concomitant achieved an odds ratio of 2.41 (95% CI= 1.80-3.24; 85% vs. 72%). If we subdivide by length of both arms the differences in efficacy between both treatments were, as expected, smaller at longer regimens due to the rapid decrease in the efficacy of standard triple therapy at shorter regimens (Fig. 2B).
Regarding tolerance, in a previously published meta-analysis [81], no severe side effects were reported in any of the manuscripts, except anaphylactic reactions to study drugs [26, 64, 70]. However, these antibiotic treatments do show a high rate